Stocks Special Reports LICs Credit Technical Analysis Funds ETFs Tools SMSFs
Learn
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features Technical Analysis SMSFs Learn
About

Market Reports

ASX Market Report

Equities/
Fixed Interest
Close Points
Changed
%
Change
Currency Close Points
Changed
%
Change
All Ordinaries 5571 -8 -0.15 $A vs $US 0.7317 0.0044 0.60
S&P/ASX 200 5585 -5 -0.09 $A vs GBP 0.4702 0.0030 0.65
  $A vs YEN 90.41 0.73 0.82
  $A vs EUR 0.6618 0.0058 0.88
  $A vs $NZ 1.0976 -0.0001 -0.01
PREMIUM To view this information
become a Premium Member
ASX Code Company Name Impact Recommendation
NVT Navitas Limited (NVT)
TEN Ten Network Holdings Limited (TEN)
AWC Alumina Limited (AWC)
FMG Fortescue Metals Group Ltd (FMG)
OSH Oil Search Limited (OSH)

Tuesday 28 July - The local market opened lower today on the back of losses on Wall Street and China overnight. However, the negativity was short-lived as stocks climbed above the flat-line mid-afternoon. Late afternoon saw the momentum stall with mixed results from big banks and a fluctuating BHP, to end the day slightly lower. There were mixed results from the sectors; energy gained most significantly whilst industrials were the biggest laggard. The Australian dollar gained against most major currencies.

The All Ordinaries fell 8.20 points (-0.15%) to 5,571.00 while the S&P/ASX 200 fell 5.20 points (-0.09%) to 5,584.70.

Charter Hall Group (CHC)

Charter Hall Group announced it has completed the sale of its interest in the development site at 685 La Trobe Street, Docklands, Melbourne for $ 31.5m (with CHC realising $15.75m for its 50% share). The sale price represents a premium to the book value at 30 June 2015 and the proceeds will be invested to generate operating earnings generated from Property Investments. CHC lost 10 cents (-2.15%) to $4.56.

CSL Limited (CSL)

CSL announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's Behring's Biologics License Application (BLA) for its novel investigational recombinant factor VIII single-chain (rVIII-SingleChain) for the treatment of haemophilia A. In the pivotal clinical trial, rVIII-SingleChain met all primary endpoints. Haemophilia A is a congenital bleeding disorder characterized by deficient or defective factor VIII. People with haemophilia A may experience prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. The condition affects 1 in 6,000 male births. CSL added $1.52 (1.61%) to $96.17.

The NZX 50 lost 23.67 points (-0.40%) to 5,848.39 while the Nikkei dropped 21.21 (-0.10%) points at the time of writing, to be last quoted at 20,328.89.

The Australian dollar was last quoted at 73.17 US cents.

© Copyright Morningstar Australasia Pty Ltd 2015 ABN 95 090 665 544 (Morningstar), AFSL 240892. (a subsidiary of Morningstar, Inc.). This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Some of the material provided is published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO").

DISCLAIMER: To the extent that any of the content above constitutes advice, it is general advice that has been prepared without reference to your objectives, financial situation or needs. Before acting on any advice, you should consider the appropriateness of the advice and we recommend you obtain appropriate financial, legal and taxation advice before making any financial investment decision. If applicable, investors should obtain the relevant product disclosure statement and consider it before making any decision to invest. Please refer to our Financial Services Guide (FSG) for more information at www.morningstar.com.au/fsg or phone Morningstar on 1800 03 44 55 to request a copy. The data and content contained herein are not guaranteed to be accurate, complete or timely. Neither Morningstar, nor its affiliates nor their content providers will have any liability for any use or distribution of any of this information.

DISCLAIMER: Employees may have an interest in the securities discussed in this report.

ASX Today

Recent Analyst Reports